全文获取类型
收费全文 | 141682篇 |
免费 | 12849篇 |
国内免费 | 7631篇 |
专业分类
耳鼻咽喉 | 1293篇 |
儿科学 | 2129篇 |
妇产科学 | 3092篇 |
基础医学 | 15144篇 |
口腔科学 | 2936篇 |
临床医学 | 17922篇 |
内科学 | 22002篇 |
皮肤病学 | 1721篇 |
神经病学 | 7134篇 |
特种医学 | 4762篇 |
外国民族医学 | 52篇 |
外科学 | 14429篇 |
综合类 | 21716篇 |
现状与发展 | 24篇 |
一般理论 | 21篇 |
预防医学 | 10035篇 |
眼科学 | 3792篇 |
药学 | 14841篇 |
134篇 | |
中国医学 | 7444篇 |
肿瘤学 | 11539篇 |
出版年
2024年 | 347篇 |
2023年 | 1772篇 |
2022年 | 4060篇 |
2021年 | 6138篇 |
2020年 | 4544篇 |
2019年 | 4178篇 |
2018年 | 4474篇 |
2017年 | 4174篇 |
2016年 | 3717篇 |
2015年 | 5871篇 |
2014年 | 7540篇 |
2013年 | 7624篇 |
2012年 | 11122篇 |
2011年 | 12005篇 |
2010年 | 8197篇 |
2009年 | 6707篇 |
2008年 | 8547篇 |
2007年 | 8416篇 |
2006年 | 8005篇 |
2005年 | 7377篇 |
2004年 | 5329篇 |
2003年 | 4865篇 |
2002年 | 4048篇 |
2001年 | 3418篇 |
2000年 | 3201篇 |
1999年 | 2969篇 |
1998年 | 1498篇 |
1997年 | 1409篇 |
1996年 | 1165篇 |
1995年 | 1108篇 |
1994年 | 1023篇 |
1993年 | 604篇 |
1992年 | 992篇 |
1991年 | 869篇 |
1990年 | 754篇 |
1989年 | 629篇 |
1988年 | 571篇 |
1987年 | 492篇 |
1986年 | 392篇 |
1985年 | 318篇 |
1984年 | 214篇 |
1983年 | 192篇 |
1982年 | 104篇 |
1981年 | 98篇 |
1979年 | 144篇 |
1978年 | 115篇 |
1977年 | 84篇 |
1974年 | 96篇 |
1973年 | 80篇 |
1972年 | 91篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
1.
目的 观察结肠癌HCT116细胞健脾消癌方的条件培养液对HUVEC细胞管腔形成的影响,从PI3K/Akt生物轴调控角度探讨其作用机制。方法 培养HCT116细胞,细胞设3组:对照组,健脾消癌方组(加入15%健脾消癌方含药血清)及人参皂苷Rg3组;制备HCT116细胞健脾消癌方条件培养液(分组及制备方法见实验方法),用条件培养液干预HUVEC(脐静脉内皮细胞,Human Umbilical Vein Endothelial Cells),Matrigel基质胶法检测HCT116细胞健脾消癌方条件培养液对HUVEC小管形成的影响。随后采用蛋白免疫印迹法(Western blot)检测各组HCT116细胞磷脂酰肌醇3-激酶(PI3K)、蛋白激酶B(Akt)、p-Akt、VEGF(血管内皮生长因子,Vascular endothelial growth factor)蛋白表达。最后在结肠癌HCT116荷瘤小鼠中验证健脾消癌方对肿瘤生长速度的影响,并经瘤组织VEGF蛋白表达、CD31免疫组化染色检测肿瘤内血管生成情况。结果 模型组HUVEC细胞管腔形成较空白血清组显著增加(P<0.05);健脾消癌方组及人参皂苷Rg3组较模型组HUVEC细胞管腔形成显著减少(P<0.01)。p-Akt和VEGF蛋白表达水平模型组高于空白血清组(P<0.05),健脾消癌方组及人参皂苷Rg3组显著低于模型组(P<0.01);PI3K、Akt蛋白表达量组间差异无统计学意义。与对照组比较,模型组荷瘤小鼠肿瘤体积显著性增大,瘤组织内VEGF表达、CD31阳性面积显著性增加,差异有统计学意义(P<0.05);与模型组比较,健脾消癌方组及人参皂苷Rg3组荷瘤小鼠肿瘤体积显著减小,瘤组织内VEGF表达、CD31阳性面积降低,差异有统计学意义(P<0.05)。结论 健脾消癌方可抑制肿瘤的血管生成和生长,其作用机制可能与PI3K/Akt生物轴调控VEGF表达有关。 相似文献
2.
3.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
4.
5.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
6.
Depeng Meng Yichen Meng Bingyang Li Guigang Zeng Bin Zhang Chunlin Hou Haodong Lin Yueping Ouyang 《Journal of orthopaedic science》2021,26(3):409-414
BackgroundComminuted patellar fractures are not rare, and the ideal treatment method remains controversial. The present study was conducted to evaluate effects and compare complications of two different methods used to treat comminuted patellar fractures.MethodsFrom March 2010 to August 2016, 102 cases of 34-C2 or 34-C3 comminuted patellar fractures were treated at our hospital, wherein patients received two different treatments: titanium cable tension band with cerclage method (group A) and intrafragmentary screws with X-shaped plating technique (group B). At follow-ups, articular step-off, range of motion (ROM), Lysholm scores, time of union, and complications were recorded and analyzed. Radiographic and clinical data as well as rate of complications were statistically analyzed.ResultsIn total, 87 patients were included in the final analysis (n = 47 in group A and n = 40 in group B). No significant differences were noted in terms of cost of implant, age, gender, rate of 34-C3 fractures, rate of layered inferior pole fractures, postoperative articular step-off and union time. At 2-year follow-up, average Lysholm scores, ROM and rate of complications were (89.0 ± 4.5), (122°±12°) and (27.7%) in group A and (90.2 ± 3.9), (124°±11°) and (17.5%) in group B, respectively, with no significant differences (p > 0.05). The mean time of surgery in group B was shorter than that in group A with significant difference (p < 0.05).ConclusionsTreatment using the intrafragmentary screws and plate method for amenable comminuted patellar fractures achieved similar complication rate and favorable functional outcomes at the 2-year follow-up, which was comparable to the titanium cable tension band with cerclage method. Thus, the intrafragmentary screws and plate method is effective, safe and convenient for 34-C2/C3 comminuted patellar fractures, especially appropriate for patients with layered fragments. 相似文献
7.
8.
Clinical and Experimental Medicine - Recently, the use of novel targeted drugs significantly improved the overall response rate (ORR) and survival of patients with relapsed/refractory chronic... 相似文献
9.
10.
We report a Chinese family with members affected by epidermolytic ichthyosis (EI), caused by KRT gene mutations. The proband was a 14‐year‐old boy who had simultaneous appearance of nephroblastoma and epidermolytic ichthyosis (EI). Both the patient and his mother exhibited the specific clinical and pathological manifestations of EI. We analysed all exons and flanking sequences of the KRT1 and KRT10 genes using PCR, and found that the proband and his mother had a G>C transition at nucleotide position 1432 in exon 7 of KRT1, resulting in an amino acid substitution of glutamate (GAA) to glutamine (CAA) at codon 478 (E478Q). The KRT10 gene had no mutations. 相似文献